This company seems to have been delisted
Reason: Acquired by AbbVie
Last recorded trade on: October 3, 2024
Source: https://news.abbvie.com/2024-08-01-AbbVie-Completes-Acquisition-of-Cerevel-Therapeutics
Reason: Acquired by AbbVie
Last recorded trade on: October 3, 2024
Source: https://news.abbvie.com/2024-08-01-AbbVie-Completes-Acquisition-of-Cerevel-Therapeutics
Cerevel Therapeutics
CERE
S$57.80
Share price
0.00%
Change (1 day)
99.26%
Change (1 year)
Categories
Cerevel Therapeutics (CERE) - Total debt
Total debt on the balance sheet as of March 2024 : S$0.47 Billion
According to Cerevel Therapeutics's latest financial reports the company's total debt is S$0.47 Billion. A company’s total debt is the sum of all current and non-current debts.
Cerevel Therapeutics - Total debt on balance sheet (from 2020 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | S$0.48 B | -1.74% |
| 2022-12-31 | S$0.49 B | 902.76% |
| 2021-12-31 | S$49.4 M | 13.16% |
| 2020-12-31 | S$43.66 M | 13.99% |
| 2019-12-31 | S$38.3 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Archer Daniels Midland (ADM)
ADM | S$15.97 B | 3,273.06% | 🇺🇸 USA |
 Dow DOW | S$23.03 B | 4,765.86% | 🇺🇸 USA |
 Dupont De Nemours DD | S$9.22 B | 1,847.86% | 🇺🇸 USA |
Campbell's CPB | S$8.86 B | 1,772.38% | 🇺🇸 USA |